TRELSTAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trelstar, and when can generic versions of Trelstar launch?
Trelstar is a drug marketed by Verity and is included in three NDAs. There is one patent protecting this drug.
This drug has forty-six patent family members in thirty-one countries.
The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the triptorelin pamoate profile page.
DrugPatentWatch® Generic Entry Outlook for Trelstar
Trelstar was eligible for patent challenges on June 15, 2004.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 30, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for TRELSTAR
| International Patents: | 46 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,342 |
| Drug Prices: | Drug price information for TRELSTAR |
| What excipients (inactive ingredients) are in TRELSTAR? | TRELSTAR excipients list |
| DailyMed Link: | TRELSTAR at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TRELSTAR
Generic Entry Date for TRELSTAR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAMUSCULAR |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TRELSTAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bristol-Myers Squibb | Phase 2 |
| Sir Mortimer B. Davis - Jewish General Hospital | Phase 2/Phase 3 |
| Medical College of Wisconsin |
Anatomical Therapeutic Chemical (ATC) Classes for TRELSTAR
US Patents and Regulatory Information for TRELSTAR
TRELSTAR is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of TRELSTAR is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting TRELSTAR
Slow release pharmaceutical composition made of microgranules
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 020715-001 | Jun 15, 2000 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 021288-001 | Jun 29, 2001 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 022437-001 | Mar 10, 2010 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRELSTAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 020715-001 | Jun 15, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 021288-001 | Jun 29, 2001 | ⤷ Try a Trial | ⤷ Try a Trial |
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 020715-001 | Jun 15, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 020715-001 | Jun 15, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| Verity | TRELSTAR | triptorelin pamoate | INJECTABLE;INTRAMUSCULAR | 022437-001 | Mar 10, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRELSTAR
When does loss-of-exclusivity occur for TRELSTAR?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
African Regional IP Organization (ARIPO)
Patent: 00
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 08259411
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0812250
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 88478
Estimated Expiration: ⤷ Try a Trial
China
Patent: 1677959
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 51234
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0161785
Estimated Expiration: ⤷ Try a Trial
Patent: 0181854
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 18434
Estimated Expiration: ⤷ Try a Trial
Patent: 20891
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 64467
Estimated Expiration: ⤷ Try a Trial
Patent: 00014
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 9284
Estimated Expiration: ⤷ Try a Trial
Patent: 0971132
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 64467
Estimated Expiration: ⤷ Try a Trial
Patent: 00014
Estimated Expiration: ⤷ Try a Trial
Patent: 31077
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 41737
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 31550
Estimated Expiration: ⤷ Try a Trial
Patent: 40391
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 2501
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 19169
Estimated Expiration: ⤷ Try a Trial
Patent: 10529106
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 64467
Estimated Expiration: ⤷ Try a Trial
Patent: 00014
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 0450
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 09012856
Estimated Expiration: ⤷ Try a Trial
Montenegro
Patent: 959
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 422
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 2423
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 64467
Estimated Expiration: ⤷ Try a Trial
Patent: 00014
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 64467
Estimated Expiration: ⤷ Try a Trial
Patent: 00014
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 591
Estimated Expiration: ⤷ Try a Trial
Patent: 248
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 64467
Estimated Expiration: ⤷ Try a Trial
Patent: 00014
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 0907940
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1631475
Estimated Expiration: ⤷ Try a Trial
Patent: 100023950
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 11020
Estimated Expiration: ⤷ Try a Trial
Patent: 94401
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 09000476
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 830
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering TRELSTAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Luxembourg | 87772 | ⤷ Try a Trial | |
| Australia | 619996 | ⤷ Try a Trial | |
| Portugal | 2164467 | ⤷ Try a Trial | |
| Japan | 5419169 | ⤷ Try a Trial | |
| Luxembourg | 87340 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
